When was Variant Bio founded?

Variant Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Variant Bio located?

Variant Bio is headquartered in Brooklyn, United States.

Who is the current CEO of Variant Bio?

Akhila Kosaraju and Andrew Farnum s of Variant Bio.

How many employees does Variant Bio have?

As of Aug 31, 2026, the latest employee count at Variant Bio is 38.

Is Variant Bio a funded company?

Variant Bio is a funded company, having raised a total of $128M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 10, 2019.

When was the latest funding round of Variant Bio?

Variant Bio's latest funding was a $***** Series B round on Nov 17, 2021, with participation from 0 investor. Its primary sector is Pulmonology. In United States, the Pulmonology sector has seen $964M in funding in 2026 to date.

Where does Variant Bio rank among its competitors?

Variant Bio ranks 3rd amongst 39 active competitors, of which 13 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Cereno Scientific, which secured $31.6M in Nov, 2025.

Who are the top competitors of Variant Bio?

Variant Bio's top competitors include 4D Molecular Therapeutics, PureTech Health and Endeavor Biomedicines. Among them, Cereno Scientific secured the most recent funding round in November, 2025.

Variant Bio - 2026 Company Profile, Team, Funding & Competitors

Variant Bio is a series B company based in Brooklyn (United States), founded in 2018 by Stephane Castel, Akhila Kosaraju and Kaja Wasik. It operates as a Developer of therapeutics for the treatment of orphan indications. Variant Bio has raised $128M in funding from Lux Capital. The company has 39 active competitors, including 13 funded and 7 that have exited. Its top competitors include companies like 4D Molecular Therapeutics, PureTech Health and Endeavor Biomedicines.

Company Details

Developer of therapeutics for the treatment of orphan indications. The company offers its platform for the detection of human genetic diversity and provides treatment solutions for rare diseases.

Website: www.variantbio.com/
Social
Email ID: *****@variantbio.com

Key Metrics

Founded Year

2018

Location

Brooklyn, United States

Stage

Series B

Total Funding

$128M in 3 rounds

Latest Funding Round

Series B, Nov 17, 2021, $*****

Investors

Lux Capital & 5 more

Ranked

3^rd among 39 active competitors

Employee Count

38 as on Aug 31, 2026

Similar Companies

4D Molecular Therapeutics & 37 more

View Variant Bio's full profile

Variant Bio has raised a total funding of $128M over 3 rounds. Its first funding round was on Oct 10, 2019. Variant Bio has 6 institutional investors.

Here is the list of recent funding rounds of Variant Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 17, 2021	8439512	Series B	3040725	8325185	3829013	9257291
Aug 05, 2020	9273494	Series A	6918833	4243554	4702949	1319560
Oct 10, 2019	3972404	Series A	2929591	6086806	Lux Capital	7323042

Access funding benchmarks and valuations. Sign up today!

View details of Variant Bio's funding rounds and investors

The founders of Variant Bio are Stephane Castel, Akhila Kosaraju and Kaja Wasik. Andrew Farnum is the CEO of Variant Bio.

Here are the details of Variant Bio's key team members:

Stephane Castel: Co-Founder of Variant Bio.
Contact Info: 1 email address
Akhila Kosaraju: Co-Founder & CEO of Variant Bio.
Kaja Wasik: Co-Founder & CSO of Variant Bio.
Andrew Farnum: CEO of Variant Bio.
Contact Info: 2 email addresses

View details of Variant Bio's Founder profiles and Board Members

Variant Bio's employee count trend

Variant Bio has 38 employees as of Aug 26. Here is Variant Bio's employee count trend over the years:

Uncover Variant Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Variant Bio include 4D Molecular Therapeutics, PureTech Health and Endeavor Biomedicines. Here is the list of Top 10 competitors of Variant Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	4D Molecular Therapeutics 2013, Emeryville (United States), Public	Developer of gene therapeutics for genetic disorders	$187M	Viking Global Investors, BVF Partners & 18 others	67/100
2nd	PureTech Health 2005, Boston (United States), Public	Developer of immunotherapeutics for multiple diseases	$107M	Vitruvian Partners, Invesco Perpetual & 1 others	66/100
3rd	Variant Bio 2018, Brooklyn (United States), Series B	Developer of therapeutics for the treatment of orphan indications	$128M	SoftBank Vision Fund, Kygo & 4 others	64/100
4th	Endeavor Biomedicines 2018, Solana Beach (United States), Series C	Developer of therapeutics for the treatment of cancer and pulmonary diseases	$296M	Longitude Capital, Omega Funds & 14 others	62/100
5th	Vandria 2018, Lausanne (Switzerland), Series A	Developer of in-vitro screening platform for drug discovery and development	$30.7M	ND Capital, Dolby Family Ventures & 1 others	58/100
6th	Redx Pharma 2010, Liverpool (United Kingdom), Acquired	Developer of small molecule medicines for fibrotic disease and oncology	-	Polar Capital, Redmile Group & 8 others	54/100
7th	Kither biotech 2010, Sant Ambrogio di Torino (Italy), Series B	Developer of treatments for rare pulmonary diseases	$26.6M	Elysia Capital, Club degli Investitori & 11 others	54/100
8th	Cereno Scientific 2012, Askim (Sweden), Public	Developer of therapeutics for cardiovascular diseases	-	Vinnova, GU Ventures	49/100
9th	DJS Antibodies 2014, Oxford (United Kingdom), Acquired	Developer of antibody therapeutics for inflammatory conditions	$36M	LifeArc, Sedgwick & 7 others	46/100
10th	Ilya Pharma 2016, Uppsala (Sweden), Series A	Biological drugs for treating wounds in skin and mucosa	$4.02M	EIC Fund, PÄAB & 6 others	45/100